Journals / Glokom Katarakt / 2014 / Cilt: 9 - Sayı: 2

New Therapeutic Approaches in Glaucoma: What's in the Future?

Glokomda Yeni Tedavi Yaklaşımları: Gelecekte Ne Var?

Pages
73–82
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this article, damage mechanisms shedding light on glaucoma physiopathology, related current treatment methods and the ideas and studies answering the question of what could be done in the future will be discussed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Glaucoma, as a multifactorial, progressive and neurodegenerative group of diseases, ends up visual loss without appropi-ate treatment.
📊
Key Findings & Data:Then effective treatment strategies might be developed.
💡
Conclusion & Impact:In this article, damage mechanisms shedding light on glaucoma physiopathology, related current treatment methods and the ideas and studies answering the question of what could be done in the future will be discussed.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Glaucoma, as a multifactorial, progressive and neurodegenerative group of diseases, ends up visual loss without appropi-ate treatment. There are cases with optic nerve damage and progression even in the presence of the normal intraocular pressure (IOP). In that case another mechanisms play role. It is possible to stop progression and control ganglion cell loss through understanding these mechanisms. Then effective treatment strategies might be developed. In this article, damage mechanisms shedding light on glaucoma physiopathology, related current treatment methods and the ideas and studies answering the question of what could be done in the future will be discussed.

Özet

Glokom, multifaktöryel, progresif ve nörodejeneratif bir hastalık grubu olup, tedavi edilmediğinde görme kaybı ile sonuçla-nır. Göz içi basınç (GİB) yüksekliği halen kontrol edilebilir tek majör risk faktörü olmakla birlikte, GİB kontrolüne rağmen ilerleme gösteren ya da GİB normal seviyede olmasına rağmen optik sinir hasarı gelişen olgular söz konusudur. Bu durum-da yüksek GİB'ndan bağımsız başka mekanizmalar devreye girmektedir. Glokomda ganglion hücre hasarının kontrol altına alınması ve ilerlemenin durdurulması bu mekanizmalara ait fizyopatolojinin iyi anlaşılması ile mümkündür. Sonuçta etkin tedavi yöntemleri ancak bu şekilde geliştirilebilir.Makalede glokomun fizyopatolojisine ışık tutan hasar mekanizmaları, bunlara ait güncel tedavi yaklaşımları ve gelecekte neler yapılabilir sorusunu aydınlatmaya yarayacak çalışma ve fikirler etraflıca irdelenecektir.

🔖

Cite This Article

SARICAOĞLU, M. S. (2014). New Therapeutic Approaches in Glaucoma: What's in the Future?. Glokom Katarakt, Cilt: 9 - Sayı: 2, 73–82. https://ajindex.com/articles/226451

References (16)

  1. Ly T, Gupta N, Weinreb RN, et al. Dendrite plasticity in the lateral geniculate nucleus in primate glaucoma.Vision Res 2011;51:243-50. Yüksel N. Nörodejeneratif hastalık olarak glokom. Türk Klin J Ophthalmol. 2012;5:14-18.
  2. Chen SD, Wang L, Zhang XL. Neuroprotection in glaucoma: present and future. Chin Med J (Engl) 2013;126:1567-77.
  3. Chang EE, Goldberg JL. Glaucoma 2.0: neuroprotection, neuroregeneration, 2012;119:979-86.
  4. Ophthalmology Vasudevan SK, Gupta V, Crowston JG. Neuroprotection in glaucoma. Indian J Ophthalmol 2011;59:102-13.
  5. Qu J, Wang D, Grosskreutz CL. Mechanisms of retinal ganglion cell injury and defense in glaucoma.Exp Eye Res 2010;91:48-53. Elgin U. Glokomda nöron koruyucu tedavi. Glo-Kat 2011;6:90-6.
  6. Payne AJ, Kaja S, Naumchuk Y, et al. Antioxidant drug ther- apy approaches for neuroprotection in chronic diseases of the retina.Int J Mol Sci 2014;15:1865-86.
  7. Agarwal R, Agarwal P. Glaucomatous neurodegeneration: an eye on tumor necrosis factor-alpha.Indian J Ophthalmol 2012;60:255-61. Shahsuvaryan M. Glaucomatous optic neuropathy manage- ment: the role of neuroprotective agents. Med Hypothesis Dis- cov Innov Ophthalmol 2013;2:41-6.
  8. Munemasa Y, Kitaoka Y. Molecular mechanisms of retinal ganglion cell degeneration in glaucoma and future pros- pects for cell body and axonal protection. Front Cell Neurosci 2013:9;6:60. Chauhan BC. Endothelin and its potential role in glaucoma. Can J Ophthalmol 2008;43:356-60.
  9. Prasanna G, Krishnamoorthy R, Yorio T. Endothelin, astro- cytes and glaucoma. Exp Eye Res 2011;93:170-7.
  10. Rosenthal R, Fromm M. Endothelin antagonism as an ac- tive principle for glaucoma therapy. Br J Pharmacol 2011;162:806-16.
  11. Chen S, Fan Q, Li A, et al. Dynamic mobilization of PGC-1? mediates mitochondrial biogenesis for the protection of RGC- 5 cells by resveratrol during serum deprivation.Apoptosis 2013;18:786-99.
  12. Sorkhabi R, Ghorbanihaghjo A, Javadzadeh A, et al. Oxida- tive DNA damage and total antioxidant status in glaucoma patients.Mol Vis 2011;17:41-6.
  13. Froger N, Jammoul F, Gaucher D, et al. Taurine is a crucial factor to preserve retinal ganglion cell survival.Adv Exp Med Biol 2013;775:69-83.
  14. Egorov EA, Gvetadze AA, Davydova NG. Antioxidant agents in neuroprotection treatment of glaucoma. Vestn Oftalmol 2013;129:69-70
  15. Steigerwalt RD, Gianni B, Paolo M, et al. Effects of Mirto- genol on ocular blood flow and intraocular hypertension in asymptomatic subjects. Mol Vis 2008;14:1288-92.
  16. Mozaffarieh M, Fraenkl S, Konieczka K, et al. Targe